serine tert-butyl ester hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: serine tert-butyl ester hydrochloride
• 英文别名: [3-Hydroxy-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]azanium;chloride；[3-hydroxy-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]azanium;chloride
• 化学式: C₇H₁₅NO₃*ClH
• 分子量: 197.662
• InChiKey: TUDHOGYHZNNYHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  serine tert-butyl ester hydrochloride 在 palladium on activated charcoal 三丁基膦 、 四丁基氟化铵 、 氢气 、 N,N-二异丙基乙胺 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 乙腈 为溶剂， -10.0~50.0 ℃ 、101.33 kPa 条件下， 反应 56.0h， 生成 2-{[2-(Bis-tert-butoxycarbonylmethyl-amino)-ethyl]-tert-butoxycarbonylmethyl-amino}-4-nitro-decanedioic acid 1-tert-butyl ester
  参考文献：
  名称：

  用于合成双功能和三功能螯合剂的新型次氮基三乙酸和乙二胺四乙酸硝基衍生物

  摘要：

  摘要 丝氨酸衍生物脱水成双脱氢氨基酸，随后与硝基甲烷共轭加成，产生了新的次氮基三乙酸和乙二胺四乙酸的硝基衍生物。这些化合物的直接转化允许通过亨利反应合成双功能和三功能金属螯合剂。

  DOI：

  10.1080/00397910500189718

文献信息

• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
• Photoredox Metal‐Free Synthesis of Unnatural <i>β</i>‐Silyl‐<i>α</i>‐Amino Acids via Hydrosilylation
  作者：Guo‐Qin Wang、Ting Wang、Yue Zhang、Yuan‐Xia Zhou、Dan Yang、Pan Han、Lin‐Hai Jing

  DOI：10.1002/asia.202300805

  日期：2023.12.14

  Structurally diverse β-silyl-α-amino acid compounds were prepared via visible-light-induced metal-free hydrosilylation of dehydroalanines and hydrosilanes.

  通过可见光诱导的脱氢丙氨酸和氢硅烷的无金属氢化硅烷化制备了结构多样的β-甲硅烷基-α-氨基酸化合物。
• Highly Enantioselective Synthesis of (<i>R</i>)-α-Alkylserines via Phase-Transfer Catalytic Alkylation of <i>o</i>-Biphenyl-2-oxazoline-4-carboxylic Acid <i>tert</i>-Butyl Ester Using <i>Cinchona</i>-Derived Catalysts
  作者：Yeon-Ju Lee、Jihye Lee、Mi-Jeong Kim、Taek-Soo Kim、Hyeung-geun Park、Sang-sup Jew

  DOI：10.1021/ol050228x

  日期：2005.4.14

  A highly enantioselective synthetic method for (R)-alpha-alkylserines was developed by the phase-transfer catalytic alkylation of o-biphenyl-2oxazoline-4-carboxylic acid tert-butyl ester (4i) using cinchona-derived phase-transfer catalyst N(1)-(9-anthracenylmethyl)-O(9)-allyi-dihydrocinchonidinium bromide (up to 96% ee).
• DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1699759A1

  公开（公告）日：2006-09-13
• Pyrrolidine Derivatives
  申请人：Qiu Yao-Ling

  公开号：US20090047247A1

  公开（公告）日：2009-02-19

  The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.